Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 May 1;101(9):1951–1959. doi: 10.1172/JCI119889

Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.

N Nakamura 1, T Ban 1, K Yamaji 1, Y Yoneda 1, Y Wada 1
PMCID: PMC508782  PMID: 9576760

Abstract

Lupus anticoagulant (LAC) is associated with arterial and venous thrombosis, thrombocytopenia, and recurrent fetal loss. We have reported previously that plasma with LAC activity induces apoptosis in endothelial cells and binds annexin V (Nakamura, N., Y. Shidara, N. Kawaguchi, C. Azuma, N. Mitsuda, S. Onishi, K. Yamaji, and Y. Wada. 1994. Biochem. Biophys. Res. Commun. 205:1488-1493). In this study, we separated two IgG antibody fractions, one with and one without affinity for annexin V, from 10 patients with LAC. LAC and apoptotic activities were localized in the annexin V-binding fraction in all 10 patients. DNA fragmentation was dose-dependent, paralleling the amount of IgG added to the human umbilical vein endothelial cell culture medium, and was inhibited by preincubation with annexin V. Removal of the antiphospholipid antibodies from patient IgG with phospholipid liposomes did not abolish the apoptosis-inducing activities or binding to annexin V. These results imply that patients with LAC often have antibodies that do not bind phospholipids and are responsible for the induction of apoptosis in endothelial cells.

Full Text

The Full Text of this article is available as a PDF (277.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahn N. G., Teller D. C., Bienkowski M. J., McMullen B. A., Lipkin E. W., de Haën C. Sedimentation equilibrium analysis of five lipocortin-related phospholipase A2 inhibitors from human placenta. Evidence against a mechanistically relevant association between enzyme and inhibitor. J Biol Chem. 1988 Dec 15;263(35):18657–18663. [PubMed] [Google Scholar]
  2. Amer L., Kisiel W., Searles R. P., Williams R. C., Jr Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res. 1990 Jan 15;57(2):247–258. doi: 10.1016/0049-3848(90)90324-6. [DOI] [PubMed] [Google Scholar]
  3. Arispe N., Rojas E., Genge B. R., Wu L. N., Wuthier R. E. Similarity in calcium channel activity of annexin V and matrix vesicles in planar lipid bilayers. Biophys J. 1996 Oct;71(4):1764–1775. doi: 10.1016/S0006-3495(96)79377-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bennett M. R., Gibson D. F., Schwartz S. M., Tait J. F. Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res. 1995 Dec;77(6):1136–1142. doi: 10.1161/01.res.77.6.1136. [DOI] [PubMed] [Google Scholar]
  5. Bevers E. M., Galli M., Barbui T., Comfurius P., Zwaal R. F. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991 Dec 2;66(6):629–632. [PubMed] [Google Scholar]
  6. Bokarewa M. I., Bremme K., Falk G., Sten-Linder M., Egberg N., Blombäck M. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res. 1995 May 1;78(3):193–200. doi: 10.1016/0049-3848(95)00048-v. [DOI] [PubMed] [Google Scholar]
  7. Bombeli T., Karsan A., Tait J. F., Harlan J. M. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997 Apr 1;89(7):2429–2442. [PubMed] [Google Scholar]
  8. Branch D. W., Rodgers G. M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):206–210. doi: 10.1016/s0002-9378(12)90915-1. [DOI] [PubMed] [Google Scholar]
  9. Branch D. W., Scott J. R., Kochenour N. K., Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med. 1985 Nov 21;313(21):1322–1326. doi: 10.1056/NEJM198511213132104. [DOI] [PubMed] [Google Scholar]
  10. Cariou R., Tobelem G., Bellucci S., Soria J., Soria C., Maclouf J., Caen J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells--inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost. 1988 Aug 30;60(1):54–58. [PubMed] [Google Scholar]
  11. Carreras L. O., Maclouf J. The lupus anticoagulant and eicosanoids. Prostaglandins Leukot Essent Fatty Acids. 1993 Jul;49(1):483–488. doi: 10.1016/0952-3278(93)90035-u. [DOI] [PubMed] [Google Scholar]
  12. Carreras L. O., Vermylen J. G. "Lupus" anticoagulant and thrombosis--possible role of inhibition of prostacyclin formation. Thromb Haemost. 1982 Aug 24;48(1):38–40. [PubMed] [Google Scholar]
  13. Casciola-Rosen L., Rosen A., Petri M., Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1624–1629. doi: 10.1073/pnas.93.4.1624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cervera R., Khamashta M. A., Font J., Ramírez G., D'Cruz D., Montalbán J., López-Soto A., Asherson R. A., Ingelmo M., Hughes G. R. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity. 1991;11(1):1–6. doi: 10.3109/08916939108994701. [DOI] [PubMed] [Google Scholar]
  15. Creutz C. E. The annexins and exocytosis. Science. 1992 Nov 6;258(5084):924–931. doi: 10.1126/science.1439804. [DOI] [PubMed] [Google Scholar]
  16. Feinstein D. I. Lupus anticoagulant, thrombosis, and fetal loss. N Engl J Med. 1985 Nov 21;313(21):1348–1350. doi: 10.1056/NEJM198511213132109. [DOI] [PubMed] [Google Scholar]
  17. Forastiero R. R., Martinuzzo M. E., Kordich L. C., Carreras L. O. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost. 1996 May;75(5):717–720. [PubMed] [Google Scholar]
  18. Freyssinet J. M., Wiesel M. L., Gauchy J., Boneu B., Cazenave J. P. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity--a mechanism for thrombosis. Thromb Haemost. 1986 Jun 30;55(3):309–313. [PubMed] [Google Scholar]
  19. Funakoshi T., Heimark R. L., Hendrickson L. E., McMullen B. A., Fujikawa K. Human placental anticoagulant protein: isolation and characterization. Biochemistry. 1987 Aug 25;26(17):5572–5578. doi: 10.1021/bi00391a053. [DOI] [PubMed] [Google Scholar]
  20. Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus. 1996 Oct;5(5):388–392. doi: 10.1177/096120339600500511. [DOI] [PubMed] [Google Scholar]
  21. Gleicher N., Harlow L., Zilberstein M. Regulatory effect of antiphospholipid antibodies on signal transduction: a possible model for autoantibody-induced reproductive failure. Am J Obstet Gynecol. 1992 Sep;167(3):637–642. [PubMed] [Google Scholar]
  22. Goossens E. L., Reutelingsperger C. P., Jongsma F. H., Kraayenhof R., Hermens W. T. Annexin V perturbs or stabilises phospholipid membranes in a calcium-dependent manner. FEBS Lett. 1995 Feb 13;359(2-3):155–158. doi: 10.1016/0014-5793(95)00032-5. [DOI] [PubMed] [Google Scholar]
  23. Harris E. N., Chan J. K., Asherson R. A., Aber V. R., Gharavi A. E., Hughes G. R. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986 Nov;146(11):2153–2156. [PubMed] [Google Scholar]
  24. Harris E. N., Gharavi A. E., Hughes G. R. Anti-phospholipid antibodies. Clin Rheum Dis. 1985 Dec;11(3):591–609. [PubMed] [Google Scholar]
  25. Ito M., Watanabe M., Ihara T., Kamiya H., Sakurai M. Fas antigen and bcl-2 expression on lymphocytes cultured with cytomegalovirus and varicella-zoster virus antigen. Cell Immunol. 1995 Feb;160(2):173–177. doi: 10.1016/0008-8749(95)80024-d. [DOI] [PubMed] [Google Scholar]
  26. Iwasaki A., Suda M., Nakao H., Nagoya T., Saino Y., Arai K., Mizoguchi T., Sato F., Yoshizaki H., Hirata M. Structure and expression of cDNA for an inhibitor of blood coagulation isolated from human placenta: a new lipocortin-like protein. J Biochem. 1987 Nov;102(5):1261–1273. doi: 10.1093/oxfordjournals.jbchem.a122165. [DOI] [PubMed] [Google Scholar]
  27. King K. B., Chubinskaya S., Reid D. L., Madsen L. H., Mollenhauer J. Absence of cell-surface annexin V is accompanied by defective collagen matrix binding in the Swarm rat chondrosarcoma. J Cell Biochem. 1997 May;65(2):131–144. doi: 10.1002/(sici)1097-4644(199705)65:2<131::aid-jcb1>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  28. Lockshin M. D. Answers to the antiphospholipid-antibody syndrome? N Engl J Med. 1995 Apr 13;332(15):1025–1027. doi: 10.1056/NEJM199504133321510. [DOI] [PubMed] [Google Scholar]
  29. Maki M., Murata M., Shidara Y. Inhibitors of platelet aggregation and blood coagulation isolated from the human placenta. Eur J Obstet Gynecol Reprod Biol. 1984 May;17(2-3):149–154. doi: 10.1016/0028-2243(84)90138-2. [DOI] [PubMed] [Google Scholar]
  30. Malia R. G., Kitchen S., Greaves M., Preston F. E. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol. 1990 Sep;76(1):101–107. doi: 10.1111/j.1365-2141.1990.tb07843.x. [DOI] [PubMed] [Google Scholar]
  31. Martinuzzo M. E., Maclouf J., Carreras L. O., Lévy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost. 1993 Oct 18;70(4):667–671. [PubMed] [Google Scholar]
  32. Matsuda R., Kaneko N., Horikawa Y. Presence and comparison of Ca2+ transport activity of annexins I, II, V, and VI in large unilamellar vesicles. Biochem Biophys Res Commun. 1997 Aug 28;237(3):499–503. doi: 10.1006/bbrc.1997.7177. [DOI] [PubMed] [Google Scholar]
  33. Matsuura E., Igarashi Y., Yasuda T., Triplett D. A., Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994 Feb 1;179(2):457–462. doi: 10.1084/jem.179.2.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. McNeil H. P., Chesterman C. N., Krilis S. A. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol. 1991;49:193–280. doi: 10.1016/s0065-2776(08)60777-4. [DOI] [PubMed] [Google Scholar]
  35. Mira J. P., Dubois T., Oudinet J. P., Lukowski S., Russo-Marie F., Geny B. Inhibition of cytosolic phospholipase A2 by annexin V in differentiated permeabilized HL-60 cells. Evidence of crucial importance of domain I type II Ca2+-binding site in the mechanism of inhibition. J Biol Chem. 1997 Apr 18;272(16):10474–10482. doi: 10.1074/jbc.272.16.10474. [DOI] [PubMed] [Google Scholar]
  36. Nakamura N., Azuma C., Akamizu T., Sugawa H., Matsuda F., Mitsuda N., Honjo T., Mori T., Yamaji K. Heterogeneity and diversity of IgM and IgG lupus anticoagulants in an individual with systemic lupus erythematosus. Biochem Biophys Res Commun. 1994 Sep 30;203(3):1789–1794. doi: 10.1006/bbrc.1994.2394. [DOI] [PubMed] [Google Scholar]
  37. Nakamura N., Kuragaki C., Shidara Y., Yamaji K., Wada Y. Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am J Hematol. 1995 Aug;49(4):347–348. doi: 10.1002/ajh.2830490414. [DOI] [PubMed] [Google Scholar]
  38. Nakamura N., Shidara Y., Kawaguchi N., Azuma C., Mitsuda N., Onishi S., Yamaji K., Wada Y. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1488–1493. doi: 10.1006/bbrc.1994.2833. [DOI] [PubMed] [Google Scholar]
  39. Nilsson T. K., Löfvenberg E. Decreased fibrinolytic capacity and increased von Willebrand factor levels as indicators of endothelial cell dysfunction in patients with lupus anticoagulant. Clin Rheumatol. 1989 Mar;8(1):58–63. doi: 10.1007/BF02031071. [DOI] [PubMed] [Google Scholar]
  40. Petri M., Rheinschmidt M., Whiting-O'Keefe Q., Hellmann D., Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med. 1987 Apr;106(4):524–531. doi: 10.7326/0003-4819-106-4-524. [DOI] [PubMed] [Google Scholar]
  41. Pierangeli S. S., Dean J., Goldsmith G. H., Branch D. W., Gharavi A., Harris E. N. Studies on the interaction of placental anticoagulant protein I, beta 2 glycoprotein 1, and antiphospholipid antibodies in the prothrombinase reaction and in the solid phase anticardiolipin assays. J Lab Clin Med. 1996 Aug;128(2):194–201. doi: 10.1016/s0022-2143(96)90011-6. [DOI] [PubMed] [Google Scholar]
  42. Rand J. H., Wu X. X., Andree H. A., Lockwood C. J., Guller S., Scher J., Harpel P. C. Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. N Engl J Med. 1997 Jul 17;337(3):154–160. doi: 10.1056/NEJM199707173370303. [DOI] [PubMed] [Google Scholar]
  43. Rao L. V., Hoang A. D., Rapaport S. I. Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Thromb Haemost. 1995 Apr;73(4):668–674. [PubMed] [Google Scholar]
  44. Raynal P., Pollard H. B. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta. 1994 Apr 5;1197(1):63–93. doi: 10.1016/0304-4157(94)90019-1. [DOI] [PubMed] [Google Scholar]
  45. Reutelingsperger C. P., Hornstra G., Hemker H. C. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem. 1985 Sep 16;151(3):625–629. doi: 10.1111/j.1432-1033.1985.tb09150.x. [DOI] [PubMed] [Google Scholar]
  46. Reutelingsperger C. P., van Heerde W. L. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997 Jun;53(6):527–532. doi: 10.1007/s000180050067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Rojas E., Pollard H. B., Haigler H. T., Parra C., Burns A. L. Calcium-activated endonexin II forms calcium channels across acidic phospholipid bilayer membranes. J Biol Chem. 1990 Dec 5;265(34):21207–21215. [PubMed] [Google Scholar]
  48. Rothhut B., Dubois T., Feliers D., Russo-Marie F., Oudinet J. P. Inhibitory effect of annexin V on protein kinase C activity in mesangial cell lysates. Eur J Biochem. 1995 Sep 15;232(3):865–872. [PubMed] [Google Scholar]
  49. Roubey R. A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. 1994 Nov 1;84(9):2854–2867. [PubMed] [Google Scholar]
  50. Roubey R. A., Eisenberg R. A., Harper M. F., Winfield J. B. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol. 1995 Jan 15;154(2):954–960. [PubMed] [Google Scholar]
  51. Roubey R. A. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996 Sep;39(9):1444–1454. doi: 10.1002/art.1780390903. [DOI] [PubMed] [Google Scholar]
  52. Roubey R. A., Maldonado M. A., Byrd S. N. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum. 1996 Sep;39(9):1606–1607. doi: 10.1002/art.1780390922. [DOI] [PubMed] [Google Scholar]
  53. Sammaritano L. R., Gharavi A. E., Lockshin M. D. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arthritis Rheum. 1990 Oct;20(2):81–96. doi: 10.1016/0049-0172(90)90021-7. [DOI] [PubMed] [Google Scholar]
  54. Sanfelippo M. J., Drayna C. J. Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am J Clin Pathol. 1982 Mar;77(3):275–279. doi: 10.1093/ajcp/77.3.275. [DOI] [PubMed] [Google Scholar]
  55. Santoro S. A. Antiphospholipid antibodies and thrombotic predisposition: underlying pathogenetic mechanisms. Blood. 1994 May 1;83(9):2389–2391. [PubMed] [Google Scholar]
  56. Schlaepfer D. D., Jones J., Haigler H. T. Inhibition of protein kinase C by annexin V. Biochemistry. 1992 Feb 18;31(6):1886–1891. doi: 10.1021/bi00121a043. [DOI] [PubMed] [Google Scholar]
  57. Schorer A. E., Wickham N. W., Watson K. V. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol. 1989 Mar;71(3):399–407. doi: 10.1111/j.1365-2141.1989.tb04298.x. [DOI] [PubMed] [Google Scholar]
  58. Simantov R., LaSala J. M., Lo S. K., Gharavi A. E., Sammaritano L. R., Salmon J. E., Silverstein R. L. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995 Nov;96(5):2211–2219. doi: 10.1172/JCI118276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Smirnov M. D., Triplett D. T., Comp P. C., Esmon N. L., Esmon C. T. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest. 1995 Jan;95(1):309–316. doi: 10.1172/JCI117657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Speijer H., Jans S. W., Reutelingsperger C. P., Hack C. E., van der Vusse G. J., Hermens W. T. Partial coverage of phospholipid model membranes with annexin V may completely inhibit their degradation by phospholipase A2. FEBS Lett. 1997 Feb 3;402(2-3):193–197. doi: 10.1016/s0014-5793(96)01527-x. [DOI] [PubMed] [Google Scholar]
  61. Tait J. F., Gibson D., Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem. 1989 May 15;264(14):7944–7949. [PubMed] [Google Scholar]
  62. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  63. Thiagarajan P., Benedict C. R. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation. 1997 Oct 7;96(7):2339–2347. doi: 10.1161/01.cir.96.7.2339. [DOI] [PubMed] [Google Scholar]
  64. Triplett D. A. Antiphospholipid antibodies: proposed mechanisms of action. Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):211–215. doi: 10.1111/j.1600-0897.1992.tb00794.x. [DOI] [PubMed] [Google Scholar]
  65. Triplett D. A. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res. 1995 Apr 1;78(1):1–31. doi: 10.1016/0049-3848(95)00001-1. [DOI] [PubMed] [Google Scholar]
  66. Tsakiris D. A., Marbet G. A., Makris P. E., Settas L., Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemost. 1989 Apr 25;61(2):175–177. [PubMed] [Google Scholar]
  67. Tsakiris D. A., Settas L., Makris P. E., Marbet G. A. Lupus anticoagulant--antiphospholipid antibodies and thrombophilia. Relation to protein C--protein S--thrombomodulin. J Rheumatol. 1990 Jun;17(6):785–789. [PubMed] [Google Scholar]
  68. Tsutsumi A., Matsuura E., Ichikawa K., Fujisaku A., Mukai M., Kobayashi S., Koike T. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996 Sep;39(9):1466–1474. doi: 10.1002/art.1780390905. [DOI] [PubMed] [Google Scholar]
  69. Vermylen J., Arnout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med. 1992 Jul;120(1):10–12. [PubMed] [Google Scholar]
  70. Wurm H. beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem. 1984;16(5):511–515. doi: 10.1016/0020-711x(84)90168-x. [DOI] [PubMed] [Google Scholar]
  71. van Heerde W. L., Poort S., van 't Veer C., Reutelingsperger C. P., de Groot P. G. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem J. 1994 Aug 15;302(Pt 1):305–312. doi: 10.1042/bj3020305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. van Heerde W. L., Sakariassen K. S., Hemker H. C., Sixma J. J., Reutelingsperger C. P., de Groot P. G. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arterioscler Thromb. 1994 May;14(5):824–830. doi: 10.1161/01.atv.14.5.824. [DOI] [PubMed] [Google Scholar]
  73. van Heerde W. L., de Groot P. G., Reutelingsperger C. P. The complexity of the phospholipid binding protein Annexin V. Thromb Haemost. 1995 Feb;73(2):172–179. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES